Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

摘要: Management of patients with lung cancer continues to pose a considerable challenge today's oncologist. While treatment may be curative in the early stages disease, majority are not diagnosed until tumor has progressed beyond primary site. Most face an intensive and invasive regimen comprising surgery, radiotherapy, or chemotherapy, combinations thereof depending on disease stage/performance status. will require chemotherapy even if their initial surgery is potentially curative; for those advanced only option. Moreover, multiple lines therapy as cells acquire resistance chemotherapeutic agents which they exposed. Resistance current chemotherapeutics available management non-small cell (NSCLC) represents one most significant barriers improving long-term outcomes this vulnerable patient group. Future lie individualizing through careful selection appropriate based likelihood response development resistance. A number biomarkers emerging that predict therapeutics; work ongoing develop algorithms such markers guide selection. In addition, novel including new platinum analogs picoplatin (a cisplatin analog), ABT-751 sulfonamide) tubulin binding (TBAs) epothilones, providing hope future.